Olsalazine Sodium — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	10-15 mg/kg	q8h (every 8 hours)	Duration: Typically 3-4 weeks for initial treatment; maintenance may be longer Notes: Administer with food to reduce gastrointestinal upset. Dosage may be adjusted based on response and tolerance. Some sources suggest 5-10 mg/kg q8h for maintenance.
Cat	PO	5-10 mg/kg	q12h (every 12 hours)	Duration: Not well established; use cautiously Notes: Limited data; use only if other therapies fail. Monitor for adverse effects.
Horse	Not applicable	Not established	Not applicable	Duration: Not applicable Notes: Not indicated for use in horses.
Cattle	Not applicable	Not established	Not applicable	Duration: Not applicable Notes: Not indicated for use in cattle.
Small Ruminants	Not applicable	Not established	Not applicable	Duration: Not applicable Notes: Not indicated for use in small ruminants.
Rabbit	Not applicable	Not established	Not applicable	Duration: Not applicable Notes: Not indicated for use in rabbits.
Bird/Poultry	Not applicable	Not established	Not applicable	Duration: Not applicable Notes: Not indicated for use in birds.
Exotic/Other	Not applicable	Not established	Not applicable	Duration: Not applicable Notes: Not indicated for use in exotic species.

Clinical Indications & Species Uses

General Indications

Treatment of inflammatory bowel disease (IBD) involving the colon
Treatment of ulcerative colitis
Maintenance of remission in colonic inflammation

Dog (Canine)

Treatment of inflammatory bowel disease (IBD), particularly colonic inflammation
Treatment of ulcerative colitis
Maintenance of remission in chronic colitis

Pharmacology & Mechanism of Action

Drug Class: 5-aminosalicylic acid (5-ASA) derivative | Pharmacological Group: Anti-inflammatory, gastrointestinal

Mechanism of Action: Olsalazine sodium is a prodrug consisting of two molecules of 5-aminosalicylic acid (5-ASA, mesalamine) linked by an azo bond. After oral administration, the drug reaches the colon where bacterial azoreductases cleave the azo bond, releasing the active moiety 5-ASA locally in the large intestine. 5-ASA acts topically on the colonic mucosa to reduce inflammation. Its exact mechanism is not fully understood, but it is known to inhibit cyclooxygenase and lipoxygenase pathways, reduce prostaglandin and leukotriene synthesis, scavenge reactive oxygen species, and modulate inflammatory cytokine production. It also inhibits nuclear factor kappa B (NF-κB) activation and reduces neutrophil chemotaxis, thereby decreasing mucosal inflammation.

Pharmacodynamics: The therapeutic effect of olsalazine is primarily local in the colon. By delivering 5-ASA directly to the site of inflammation, it reduces mucosal inflammation and helps maintain remission in ulcerative colitis. The drug has minimal systemic anti-inflammatory activity because the released 5-ASA is poorly absorbed from the colon. The onset of action is gradual, with clinical improvement typically seen within 3-7 days of therapy. The drug does not have analgesic or antipyretic properties.

⚡ Pharmacokinetics Summary

Absorption: Olsalazine is poorly absorbed from the small intestine; less than 2-3% of the dose is absorbed systemically as intact olsalazine. The majority of the drug reaches the colon intact, where it is converted to 5-ASA by bacterial azoreductases. The released 5-ASA is poorly absorbed from the colonic lumen, with only about 20-30% absorbed systemically. In dogs, oral bioavailability of intact olsalazine is low, and the drug is designed to act locally.

Distribution: The absorbed fraction of olsalazine and 5-ASA is distributed mainly in the systemic circulation. 5-ASA is bound to plasma proteins to a moderate degree (approximately 40-50%). The drug does not cross the blood-brain barrier significantly. In the colon, high local concentrations of 5-ASA are achieved, which is the primary site of action.

Metabolism: Olsalazine is metabolized in the colon by bacterial azoreductases to release two molecules of 5-ASA. The 5-ASA is further metabolized in the intestinal mucosa and liver to N-acetyl-5-ASA, which is pharmacologically inactive. The acetylation is mediated by N-acetyltransferases.

Excretion: The majority of the drug (approximately 90%) is excreted in the feces, either as unabsorbed olsalazine or as 5-ASA and its metabolites. The absorbed fraction is excreted primarily in the urine as N-acetyl-5-ASA and other metabolites. In dogs, the elimination half-life of 5-ASA is approximately 1-2 hours, but the local colonic residence time is prolonged due to slow release.

Half-Life: Dog: 1-2 hours (for 5-ASA); Cat: not well documented; Horse: not well documented; Cattle: not well documented.

Bioavailability: Oral bioavailability of intact olsalazine is very low (<3%). The systemic bioavailability of 5-ASA from olsalazine is approximately 20-30% in dogs, but the drug is designed for local colonic action.

Protein Binding: 5-ASA: approximately 40-50% bound to plasma proteins; olsalazine: approximately 90% bound.

Available Formulations & Strengths

Oral Capsule 250 mg (PO)

Oral Tablet 250 mg, 500 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to olsalazine, mesalamine, or salicylates
History of salicylate-induced asthma or hypersensitivity reactions
Severe renal impairment (due to potential accumulation of 5-ASA)
Severe hepatic impairment (use with caution)
Gastrointestinal obstruction or stenosis

Warnings & Clinical Precautions:

Use with caution in patients with renal disease; monitor renal function periodically.
Use with caution in patients with hepatic disease.
May cause diarrhea, which can be dose-dependent; reduce dose or discontinue if severe.
In dogs, olsalazine may cause hemolytic anemia in some individuals, especially with high doses or prolonged use.
Not recommended for use in cats due to lack of safety and efficacy data.
Avoid use in pregnant or lactating animals unless benefits outweigh risks.
Do not crush or break capsules/tablets; administer whole to ensure colonic delivery.
Monitor for signs of pancreatitis (rare).

Adverse Effects & Reactions

Common:

Diarrhea (dose-related)
Vomiting
Decreased appetite
Flatulence
Abdominal discomfort

Serious / Severe:

Hemolytic anemia (especially in dogs)
Renal toxicity (interstitial nephritis)
Hepatotoxicity
Pancreatitis
Exacerbation of colitis (rare)

Rare:

Hypersensitivity reactions (rash, fever)
Blood dyscrasias (leukopenia, thrombocytopenia)
Pericarditis
Pulmonary toxicity (fibrosis)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Azathioprine or 6-mercaptopurine	Potential increased risk of bone marrow suppression; monitor hematology.	Moderate
Warfarin or other anticoagulants	May enhance anticoagulant effect; monitor coagulation parameters.	Moderate
Digoxin	May reduce absorption of digoxin; monitor digoxin levels.	Mild
NSAIDs	Increased risk of renal toxicity; use with caution.	Moderate
Corticosteroids	Potential additive gastrointestinal effects; monitor for ulceration.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe diarrhea
Vomiting
Lethargy
Dehydration
Electrolyte imbalances
Renal failure (with massive overdose)
Hemolytic anemia (in dogs)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Induce emesis if recent ingestion and the animal is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids to correct dehydration and electrolyte imbalances. Monitor renal function, hematology, and electrolytes. In severe cases, consider hemodialysis for removal of 5-ASA. Discontinue the drug immediately.

Food Animal Withdrawal Times

Not approved for use in food-producing animals. Withdrawal times are not established. Do not use in food animals.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature, 20-25°C (68-77°F)

Handling & Special Conditions: Protect from moisture. Keep container tightly closed.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Dipentum) for ulcerative colitis.

Extra-Label (Off-Label) Use: In the US, olsalazine is not FDA-approved for veterinary use; however, it may be prescribed legally under the Animal Medicinal Drug Use Clarification Act (AMDUCA) for extra-label use in animals, provided a valid veterinarian-client-patient relationship exists and appropriate withdrawal times are observed for food animals. Since it is not approved for food animals, extra-label use in food animals is prohibited unless a specific exemption applies.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Olsalazine sodium is a prodrug of 5-ASA used primarily in dogs for the treatment of inflammatory bowel disease (IBD) affecting the colon, such as lymphocytic-plasmacytic colitis and ulcerative colitis. It is not commonly used in cats due to limited safety data and potential toxicity. The drug is designed to deliver 5-ASA directly to the colon, minimizing systemic absorption and side effects. Clinical response may take up to 3-4 weeks; if no improvement is seen, reassess the diagnosis and consider alternative therapies. Common adverse effects include dose-related diarrhea, which can be managed by dose reduction or dividing the dose. Serious adverse effects such as hemolytic anemia have been reported in dogs, so baseline and periodic hematology are recommended. Olsalazine should be used with caution in patients with renal or hepatic disease. It is not approved for food animals, and extra-label use in such species is prohibited. Always follow current veterinary guidelines and monitor patients closely during therapy.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)